Grandway Advised Yiling Pharmaceutical on the Project of SCP

Shijiazhuang Yiling Pharmaceutical Co., Ltd. has obtained Notice of Acceptance of Registration (NAFMII No. [2022] SCP505) issued by National Association of Financial Market Institutional Investors (“NAFMII”) for the project of Super & Short-term Commercial Paper (“SCP”).

Shijiazhuang Yiling Pharmaceutical Co., Ltd. is listed on Shenzhen Stock Exchange, with the stock abbreviation “Yiling Pharmaceutical” and the stock code “002603”. Founded by Wu Yiling, an academician of Chinese Academy of Engineering, Yiling Pharmaceutical always adheres to science and technology as the guide, insists on the development strategy of science and technology innovation with the market as the leader. Yiling Pharmaceutical has created a unique operation model of “Theory - Clinical - Research - Industry - Teaching”, and has established an innovative technology system of new drug R&D guided by innovation of the theory of collateral diseases in traditional chinese medicine. The registered amount of the project of SCP is RMB 2 billion, and the registered amount is valid for 2 years from the date of notification. The funds raised will be used to supply the needs of Yiling Pharmaceutical’s daily working capital and repay bank loans. The project will help optimize the company’s debt structure and further improve the company’s financial management.